MX2020014120A - Agonistas parciales del receptor de insulina. - Google Patents

Agonistas parciales del receptor de insulina.

Info

Publication number
MX2020014120A
MX2020014120A MX2020014120A MX2020014120A MX2020014120A MX 2020014120 A MX2020014120 A MX 2020014120A MX 2020014120 A MX2020014120 A MX 2020014120A MX 2020014120 A MX2020014120 A MX 2020014120A MX 2020014120 A MX2020014120 A MX 2020014120A
Authority
MX
Mexico
Prior art keywords
partial agonists
insulin receptor
receptor partial
insulin
dimers
Prior art date
Application number
MX2020014120A
Other languages
English (en)
Inventor
Songnian Lin
Yuping Zhu
Pei Huo
Christina B Madsen-Duggan
zhi-cai Wu
Yingjun Mu
Ravi Nargund
Lin Yan
Dmitri Pissarnitski
Danqing Feng
Ahmet Kekec
Zhi- Cai Shi
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2020014120A publication Critical patent/MX2020014120A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se divulgan dímeros de insulina y dímeros de análogo de insulina que actúan como agonistas parciales en el receptor de insulina.
MX2020014120A 2014-11-21 2017-05-19 Agonistas parciales del receptor de insulina. MX2020014120A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082857P 2014-11-21 2014-11-21
US201562242503P 2015-10-16 2015-10-16

Publications (1)

Publication Number Publication Date
MX2020014120A true MX2020014120A (es) 2021-03-25

Family

ID=54838417

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017006651A MX2017006651A (es) 2014-11-21 2015-11-19 Agonistas parciales del receptor de insulina.
MX2020014120A MX2020014120A (es) 2014-11-21 2017-05-19 Agonistas parciales del receptor de insulina.
MX2020014121A MX2020014121A (es) 2014-11-21 2017-05-19 Agonistas parciales del receptor de insulina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017006651A MX2017006651A (es) 2014-11-21 2015-11-19 Agonistas parciales del receptor de insulina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020014121A MX2020014121A (es) 2014-11-21 2017-05-19 Agonistas parciales del receptor de insulina.

Country Status (27)

Country Link
US (4) US10017556B2 (es)
EP (4) EP3221343B1 (es)
JP (5) JP6484337B2 (es)
KR (2) KR102101136B1 (es)
CN (2) CN112494656B (es)
AR (1) AR102712A1 (es)
AU (3) AU2015349890B2 (es)
BR (2) BR122024000898A2 (es)
CA (2) CA2966765C (es)
CL (3) CL2017001288A1 (es)
CO (1) CO2017004976A2 (es)
CR (1) CR20170208A (es)
DO (1) DOP2017000124A (es)
EA (1) EA036714B1 (es)
ES (1) ES2946247T3 (es)
GT (1) GT201700104A (es)
IL (1) IL252257A0 (es)
MX (3) MX2017006651A (es)
NI (1) NI201700060A (es)
PE (1) PE20170957A1 (es)
PH (1) PH12017500935A1 (es)
SG (4) SG10201809428UA (es)
SV (1) SV2017005445A (es)
TN (1) TN2017000178A1 (es)
TW (1) TW201625673A (es)
WO (1) WO2016081670A2 (es)
ZA (1) ZA201703238B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102538658B1 (ko) 2014-08-04 2023-05-31 누에볼루션 에이/에스 염증성, 대사성, 종양성 및 자가면역성 질환의 치료에 유용한 피리미딘의 임의적 융합 헤테로시클릴-치환 유도체
EA036714B1 (ru) 2014-11-21 2020-12-10 Мерк Шарп И Доум Корп. Частичные агонисты инсулинового рецептора
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
EP3922260A3 (en) * 2016-05-24 2022-06-15 Merck Sharp & Dohme Corp. Insulin receptor partial agonists and glp-1 analogues
US10689430B2 (en) 2016-05-25 2020-06-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
CN109891237B (zh) * 2016-10-24 2022-08-23 诺和诺德股份有限公司 胰岛素制剂的生物测定法
US10919949B2 (en) 2017-08-17 2021-02-16 Novo Nordisk A/S Acylated insulin analogues and uses thereof
CN112912499A (zh) 2018-08-02 2021-06-04 达因疗法公司 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3829595A4 (en) 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF DYSTROPHINOPATHIES
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
CN112898172B (zh) * 2019-12-04 2022-05-31 中国科学院大连化学物理研究所 可被羧肽酶酶解的双亲和功能团化合物的合成方法
CA3160522A1 (en) 2019-12-20 2021-06-24 Sanne Schroder Glad Compounds active towards nuclear receptors
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
JP2023540746A (ja) * 2020-09-03 2023-09-26 ダイン セラピューティクス，インコーポレーテッド タンパク質－オリゴヌクレオチド複合体の調製方法
WO2022055877A2 (en) * 2020-09-09 2022-03-17 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
WO1996034882A1 (en) 1995-05-05 1996-11-07 Eli Lilly And Company Single chain insulin with high bioactivity
CA2318806A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding agents that modulate the 5-ht transporter
DE19908041A1 (de) * 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
US7105314B2 (en) 2001-04-02 2006-09-12 Novo Nordisk A/S Method for making human insulin precursors
EP2226316B1 (en) 2002-05-30 2016-01-13 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
KR100507796B1 (ko) 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
ES2369895T3 (es) 2003-12-03 2011-12-07 Novo Nordisk A/S Insulina monocatenaria.
EP1807105A2 (en) 2004-10-27 2007-07-18 Novo Nordisk A/S Insulin receptor binding peptides with non-insulin gene activation profiles and uses thereof
ES2545533T3 (es) 2004-11-01 2015-09-11 The Regents Of The University Of California Composiciones y métodos para modificación de biomoléculas
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
EP1991575A1 (en) 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
WO2007104737A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104734A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
US20090099065A1 (en) 2006-03-13 2009-04-16 Novo Nordisk A/S Acylated Single Chain Insulin
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
EP2296692A4 (en) 2008-04-22 2012-06-06 Univ Case Western Reserve INSULIN ANALOGUES SPECIFIC TO ISOFORMS
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
PT3228320T (pt) * 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2376520B1 (en) 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
WO2011059895A1 (en) 2009-11-11 2011-05-19 Quest Diagnostics Investments Incorporated Hexa mutations
US8940860B2 (en) 2010-06-16 2015-01-27 Indiana University Research And Technology Corporation Single-chain insulin agonists exhibiting high activity at the insulin receptor
US8255297B2 (en) 2010-07-20 2012-08-28 Facebook, Inc. Creation, redemption, and accounting in a virtual currency system
US20140315797A1 (en) * 2010-10-15 2014-10-23 Peter Madsen Novel N-Terminally Modified Insulin Derivatives
WO2013063572A1 (en) * 2011-10-27 2013-05-02 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations
CA2886228A1 (en) * 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
EP2968472A1 (en) 2013-03-15 2016-01-20 Université de Genève Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production
AU2014329567B2 (en) * 2013-10-04 2019-07-25 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
EP3068443B1 (en) * 2013-11-12 2019-04-10 Centre for Probe Development and Commercialization Residualizing linkers and uses thereof
CN116987172A (zh) 2014-01-20 2023-11-03 韩美药品株式会社 长效胰岛素及其用途
EA036714B1 (ru) 2014-11-21 2020-12-10 Мерк Шарп И Доум Корп. Частичные агонисты инсулинового рецептора

Also Published As

Publication number Publication date
MX2017006651A (es) 2017-08-21
JP2020097572A (ja) 2020-06-25
US10183981B2 (en) 2019-01-22
SG10201809428UA (en) 2018-11-29
BR112017010481A8 (pt) 2023-04-11
JP2019014734A (ja) 2019-01-31
AU2015349890A1 (en) 2017-06-01
ES2946247T3 (es) 2023-07-14
US20170107268A1 (en) 2017-04-20
JP6931033B2 (ja) 2021-09-01
CN112494656A (zh) 2021-03-16
AU2018211208A1 (en) 2018-08-16
EP3666792A2 (en) 2020-06-17
PH12017500935A1 (en) 2017-11-27
US20190092833A1 (en) 2019-03-28
AU2015349890B2 (en) 2018-08-30
JP6943825B2 (ja) 2021-10-06
JP2019014735A (ja) 2019-01-31
CA2966765A1 (en) 2016-05-26
US20170355743A1 (en) 2017-12-14
EP3221343B1 (en) 2020-09-16
AU2018211208B2 (en) 2020-09-10
EP3221343A2 (en) 2017-09-27
JP6484337B2 (ja) 2019-03-13
SV2017005445A (es) 2018-04-04
PE20170957A1 (es) 2017-07-13
US20180291078A1 (en) 2018-10-11
WO2016081670A2 (en) 2016-05-26
KR102049647B1 (ko) 2019-11-29
CN108064173A (zh) 2018-05-22
EP3666792A3 (en) 2020-07-29
EP3660040A3 (en) 2020-07-29
AR102712A1 (es) 2017-03-22
CN108064173B (zh) 2021-05-18
BR122024000903A2 (pt) 2024-02-27
CL2019001144A1 (es) 2019-07-19
CA3014641C (en) 2020-08-18
BR112017010481A2 (pt) 2018-04-03
EP3660041A1 (en) 2020-06-03
CO2017004976A2 (es) 2017-10-10
WO2016081670A3 (en) 2016-08-04
CA2966765C (en) 2020-04-14
TW201625673A (zh) 2016-07-16
AU2018211207A1 (en) 2018-08-16
MX2020014121A (es) 2021-03-25
SG10201809427SA (en) 2018-11-29
EP3660041B1 (en) 2023-04-19
BR122024000898A2 (pt) 2024-02-27
AU2018211207B2 (en) 2020-04-09
KR20190069622A (ko) 2019-06-19
EP3660040A2 (en) 2020-06-03
EA201791117A1 (ru) 2017-11-30
IL252257A0 (en) 2017-07-31
CR20170208A (es) 2017-07-17
JP6703068B2 (ja) 2020-06-03
NI201700060A (es) 2017-07-18
KR20170084300A (ko) 2017-07-19
GT201700104A (es) 2018-11-27
CN112494656B (zh) 2024-01-30
JP2018501203A (ja) 2018-01-18
SG11201704064TA (en) 2017-06-29
ZA201703238B (en) 2018-05-30
KR102101136B1 (ko) 2020-04-14
CL2019001143A1 (es) 2019-07-19
US10017556B2 (en) 2018-07-10
SG10201809457YA (en) 2018-11-29
DOP2017000124A (es) 2017-08-15
TN2017000178A1 (en) 2018-10-19
CA3014641A1 (en) 2016-05-26
US10800827B2 (en) 2020-10-13
JP2019011357A (ja) 2019-01-24
EA036714B1 (ru) 2020-12-10
CL2017001288A1 (es) 2017-12-15

Similar Documents

Publication Publication Date Title
MX2020014121A (es) Agonistas parciales del receptor de insulina.
PH12016502142B1 (en) Anti-ptk7 antibody-drug conjugates
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
IN2015DE00625A (es)
SI3220893T1 (sl) Sestavek na osnovi COQ10
EP3045751A4 (en) OSCILLATING SKATE BEARING
RS61160B1 (sr) Dijetetska kompozicija sa antilipidemijskom aktivnošću
NZ719451A (en) Glucagon analog for treatment of severe hypoglycemia
HUE053676T2 (hu) Új promoter és alkalmazása
EA201991576A1 (ru) Частичные агонисты инсулинового рецептора
UA99992U (ru) 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния
AP00748S1 (en) Desks
AU358556S (en) Strap fastener
GB201501738D0 (en) S.o.s.i.c.h.
IN2014CH00927A (es)
GB201417023D0 (en) Bizyfy.com
IN2014MU03184A (es)
GB201412127D0 (en) The cigarillo
GB201416411D0 (en) Trenchcover with retainer
GB201413121D0 (en) The E.M.S As Pripulsian
GB201403059D0 (en) The S.E.G
GB201400885D0 (en) MagneticChess.com
GB201400595D0 (en) The E.M.S as propotsion